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ABSTRACT
Mesenchymal stem cells (MSCs) may be derived from adult bone marrow, fat, and several fetal tissues. In vitro,
MSCs can be expanded and have the capacity to differentiate into several mesenchymal tissues, such as bone,
cartilage, and fat. They escape the immune system in vitro, and this may make them candidates for cellular
therapy in an allogeneic setting. They also have immunomodulatory effects, inhibit T-cell proliferation in
mixed lymphocyte cultures, prolong skin allograft survival, and may decrease graft-versus-host disease
(GVHD) when cotransplanted with hematopoietic stem cells. MSCs induce their immunosuppressive effect via
a soluble factor. Some candidates have been suggested, and various mechanisms have also been suggested,
although contradictory data exist; this may be due to differences in the cells and systems tested. A major
problem has been that it has been difficult to identify and isolate MSCs after transplantation in vivo. However,
MSCs seem to enhance hematopoietic engraftment in recipients of autologous and allogeneic grafts. Recently,
they were found to reverse grade IV acute GVHD of the gut and liver. No tolerance was induced, however.
Controlled studies are warranted. Thus, in allogeneic stem cell transplantation, MSCs may be used for
hematopoiesis enhancement, as GVHD prophylaxis, and for the treatment of severe acute GVHD. They are
also of potential use in the treatment of organ transplant rejection and in autoimmune inflammatory bowel
disorders where immunomodulation and tissue repair are needed.
© 2005 American Society for Blood and Marrow Transplantation
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Stem cells are characterized by a capacity for self-
enewal and an ability to differentiate into at least 1
ature cell type. In addition to hematopoietic stem
ells (HSCs), bone marrow also contains mesenchy-
al stem cells (MSCs). Although MSCs do not fulﬁll
ll criteria for a true stem cell, they have been so called
or convenience. MSCs were ﬁrst recognized by
riedenstein and associates, who identiﬁed an adher-
nt, ﬁbroblast-like population that could regenerate
udiments of normal bone in vivo [1-4]. Apart from
ostnatal marrow, MSCs have also been isolated from
dipose tissue and fetal liver, blood, bone marrow, r
B & M Tung, and cord blood [5-8]. They have the capacity to
ifferentiate in vitro and in vivo into several mesen-
hymal tissues, including bone, cartilage, tendon,
uscle, adipose tissue, and, possibly, bone marrow
troma [9-11].
As progenitors of well-differentiated tissues, MSCs
ave enticed researchers to explore their role in re-
enerative medicine. Their use to create new bone in
egmental bone defects has been demonstrated in the
thymic rat implanted with human MSCs and in a
anine model using autologous MSCs [12-14]. Fur-
hermore, culture-expanded MSCs have been demon-
trated to regenerate articular cartilage defects and
epair Achilles tendon ruptures in rabbit models [15-
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37]. Human synovial membrane–derived MSCs en-
raft and differentiate into muscle cells in a mouse
odel of muscular dystrophy [18]. Under certain con-
itions, MSCs may acquire a cardiomyogenic pheno-
ype [19]. Several attempts have been made to make
SCs engraft in the myocardium, but it has been
ontroversial whether MSCs undergo in situ differen-
iation [20-22]. However, there are no data showing
unctional integration of MSCs into cardial muscle. It
herefore remains to be proven whether MSCs will
lay a role in cellular cardiomyoplasty. Adipocytes
erived from MSCs are functional and may be of value
n adipocyte research as a renewable source of adipo-
ytes [23]. MSCs have been suggested to be precursor
ells for the bone marrow stroma that provides a
-dimensional scaffold and enhances proliferation of
SCs. They may therefore also enhance engraftment
fter autologous or allogeneic stem cell transplanta-
ion (ASCT).
MSCs possess immunomodulatory properties and
nhibit T-cell proliferation in vitro [24-29]. An immu-
osuppressive effect of MSCs in vivo has been shown
n a baboon model, in which infusion of ex vivo–
xpanded matched donor or third-party MSCs de-
ayed the time to rejection of histoincompatible skin
rafts [25]. An immunosuppressive function of MSC
rafts in human beings, as a corollary to the immuno-
uppressive effect of MSCs in vitro and in preclinical
nimal models, suggests that MSCs may be used for
he prevention and treatment of graft-versus-host dis-
ase (GVHD) in ASCT, in organ transplantation to
revent rejection, and in autoimmune disorders. Se-
ere acute GVHD is associated with high mortality
nd is a major threat to successful ASCT [30-32].
urrently, no effective therapy exists for severe ste-
oid-refractory acute GVHD [33-42]. A variety of
rugs and antibodies have been used, mostly with
iscouraging results. Recently, MSCs were used to
uccessfully treat a 9-year-old boy with severe treat-
ent-resistant acute GVHD; this suggests that they
ave a powerful immunosuppressive effect in humans
43]. This review will deal with MSC expansion,
hich is necessary for clinical use. Furthermore, we
ill brieﬂy present surface markers, cytokine produc-
ion, and interaction with hematopoietic cells, to un-
erstand the role of MSCs in hematopoiesis. A major
ocus is on immune escape and immunosuppression of
SCs, which so far are dominated by in vitro studies.
everal mechanisms behind the immunomodulatory
ffect have been suggested. We have, among other
hings, tried to explain the divergent ﬁndings. Finally,
e have reviewed the limited clinical experience with
sing MSC in HSC transplantation, focusing on their
otential role for prophylaxis and treatment of acute
VHD. s
22SC EXPANSION
Expansion of MSCs is a necessity for clinical use.
ost information regarding the phenotypic and func-
ional properties of the cells we refer to as MSCs
omes from studies performed on cells expanded ex
ivo. Plating studies indicate that MSCs are rare in the
uman body [10,44-47]. Relatively little is known
bout the characteristics of the primary precursor cells
n vivo. One problem is the inability to prospectively
solate MSCs because of their rarity and the lack of
arkers to facilitate their isolation and enrichment.
MSCs are rare in the human body but can be
xpanded in vitro to hundreds of millions of cells from
10- to 20-mL bone marrow aspirate [9,44-47]. Iso-
ated from other cells in the bone marrow by adher-
nce to plastic and consecutive passaging, MSCs pro-
iferate to spindle-shaped cells in conﬂuent cultures.
lthough homogeneous by light microscopy, even
ingle cell–derived colonies form a molecularly heter-
geneous population of cells that vary to some extent
n their differentiative capacity [10,48,49]. Even if
SCs rapidly expand 1 billion-fold, individual cells
n a culture exhibit a highly variable expansion poten-
ial [46,50-54]. Furthermore, the cell yield after ex-
ansion varies with the age and condition of the donor
nd with the harvesting techniques [46,50,54-57].
aturally, differences in isolation techniques, culture
onditions, media additives, and subculturing tech-
iques greatly affect cell yield and possibly also the
henotype of the expanded cell product [58].
Is the MSC a true stem cell? The gene expression/
roteomics of MSCs that have been culture expanded
epend on the culture conditions, passage, species,
nd other factors or may or may not reﬂect in vivo
vents. One may therefore question whether MSCs
re real stem cells, because there seems to be an
xpansion limit. MSCs have not been demonstrated in
ivo at a single-cell level to be capable of regenerating
r maintaining a tissue compartment. One problem
oncerning MSCs is the inability to prospectively iso-
ate MSCs from tissue, characterize them, and observe
heir biologic properties. According to a less distinct
eﬁnition, MSCs have the capacity for self-renewing
nd giving rise to 1 or more types of differentiated
rogeny. In vitro, MSCs have vast proliferative poten-
ial, can clonally regenerate, and can give rise to dif-
erentiated progeny. So far, the designation of MSCs
s stem cells is based on extrapolation of in vitro data.
ore in vivo data showing the therapeutic potential
nd biology of MSCs is required before they can be
laimed to be true stem cells. Moderate subcultivation
ill not change the karyotype or telomerase activity of
SCs, but if the cells are cultured beyond the Hay-
ick limit of approximately 50 population doublings,
igns of senescence and apoptosis appear [46,50,51].
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Mesenchymal Stem Cells Against GVHD
Btromal precursors can be found in the peripheral
lood of mice, but whether MSCs circulate in the
loodstream of humans to repair injured tissues re-
ains an open question [59]. MSCs have been de-
ected in the peripheral blood of granulocyte colony-
timulating factor–mobilized breast cancer patients,
ut not in peripheral blood collected from healthy
onors [60-63].
DHESION MOLECULES, CYTOKINE PRODUCTION,
ND INTERACTIONS WITH HEMATOPOIETIC CELLS
There is a need for a quantitative assay to assess
SCs in a given population, because there is no spe-
iﬁc marker or combination of markers that speciﬁ-
ally identiﬁes MSCs. Therefore, MSCs have been
eﬁned by using a combination of phenotypic markers
nd functional properties. Controversy still exists over
he in vivo phenotype of MSC; however, ex vivo–
xpanded MSCs do not express the hematopoietic
arkers CD34, CD45, or CD14 [10,64]. In addition
o their stem cell characteristics of self-renewal, high
roliferative capacity, and multipotentiality, they can
e identiﬁed as cells that stain positive for CD73,
D105, CD166, CD90, and CD29 by ﬂow cytometry
10,11,65-67].
It has been speculated that MSCs participate in
he marrow microenvironment, because MSCs pro-
uce a vast array of matrix molecules, including ﬁ-
ronectin, laminin, collagen, and proteoglycans
10,51,68-70]. They also express various integrin -
nd -subunits and their noncovalent associations that
onstitute receptors for extracellular matrix compo-
ents, including collagen (11 and 21), laminin
61 and 64), ﬁbronectin (31 and 51), and
itronectin (v1 and v3) [10,51,65,71]. It is likely
hat MSCs play a role in the organization of the
xtracellular matrix. Characterization of surface mol-
cules by ﬂow cytometry has determined that MSCs
lso express ligands for surface molecules present on
ells of the hematopoietic lineage, including intercel-
ular adhesion molecule (ICAM)–1, ICAM-2, vascular
ell adhesion molecule 1, lymphocyte function–asso-
iated antigen 3, CD72, and activated leukocyte cel-
ular adhesion molecule [10,51,65,72,73]. In coculture
xperiments, MSCs form cell clusters with HSCs,
ncluding megakaryocytes and osteoclast progenitors
74,75]. At the same time as they provide physical
upport for HSCs, they constitutively secrete cyto-
ines important for HSC differentiation [65,72,74-
7]. When cocultured with hematopoietic progenitors
n vitro, MSCs have the capacity to maintain and
xpand lineage-speciﬁc colony-forming units from
D34 marrow cells in long-term bone marrow cul-ure [75,78]. e
B & M TStromal cells are also essential for lymphopoiesis.
arly B cells adhere to stromal cells, and differentia-
ion does not occur when lymphocytes and stromal
ells are separated in a diffusion chamber system
79,80]. Immature T cells preferentially adhere to
esenchymal bone marrow stroma, which, at least in
ulture, supplies the appropriate stimuli for prolifera-
ion of thymus precursor cells [81,82]. Moreover, do-
or-derived stromal cells in bone marrow migrate into
he thymus and participate in the positive selection of
cells after bone marrow transplantation plus bone
rafts [83].
Both CD4 and CD8 lymphocytes bind to
SCs, and the afﬁnity is increased for activated T
ells [71]. Several adhesion molecules expressed by
SCs are essential for the interaction with T cells.
ascular cell adhesion molecule 1, ICAM-2, and lym-
hocyte function–associated antigen 3 are present on
nstimulated MSCs, whereas the expression of
CAM-1 is inducible [10,27,65,71].
SCS ESCAPE THE IMMUNE SYSTEM IN VITRO
MSCs seem to escape the immune system, and this
akes them potentially useful for various transplanta-
ion purposes. Adult MSCs express intermediate levels
f HLA major histocompatibility complex (MHC)
lass I molecules. The expression on fetal MSCs is
ower [10,27,65,84,85]. Adult MSCs do not express
LA class II antigens of the cell surface. However,
LA class II is readily detectable by Western blot on
hole-cell lysates of unstimulated adult MSCs, thus
uggesting that MSCs contain intracellular deposits of
LA class II alloantigens [84]. Cell-surface expression
an be induced by treatment of the cells with inter-
eron (IFN)– for 1 or 2 days. Unlike adult MSCs, the
etal liver–derived cells have no HLA class II intra-
ellularly or on the cell surface [85]. The presence of
FN- in the growth medium for 2 days initiated the
ntracellular synthesis of HLA class II in fetal MSCs,
lthough 7 days of exposure was required for cell
urface expression. After differentiation of MSCs into
one, cartilage, or adipose tissue, both adult and fetal
SCs continued to express HLA class I, but not class
I [84,85].
In vitro, undifferentiated MSCs fail to elicit a
roliferative response from allogeneic lymphocytes,
hus suggesting that the cells are not inherently im-
unogenic [24,26,27,86]. When precultured with
FN- for full HLA class II expression, MSCs still
scape recognition by alloreactive T cells [84,85]. In
oculture experiments, MSCs differentiated into adi-
ocytes, osteoblasts, and chondrocytes, like undiffer-
ntiated MSC, are nonimmunogenic [84,85]. How-
ver, in vivo, limited data demonstrate the persistence
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3f allogeneic MSCs after transplantation into immu-
ocompetent hosts. Therefore, the question of
hether MSCs are recognized by an intact allogeneic
mmune system in vivo remains open, although the in
itro data support the theory that MSCs escape the
mmune system.
MSCs do not express FAS ligand or costimulatory
olecules, such as B7-1, B7-2, CD40, or CD40L
27,87]. When costimulation is inadequate, T-cell
roliferation can be induced by the addition of exog-
nous costimulation. However, MSCs differ from
ther cell types, and no T-cell proliferation can be
bserved when they are cultured with HLA-mis-
atched lymphocytes in the presence of a CD28-
timulating antibody [27]. One potential avenue for
he initiation of graft rejection is bystander activation.
iven that the proportion of T cells with allospeciﬁc-
ty is estimated to be 1% to 5% in the course of an
nfection, T cells that are capable of recognizing
SCs or their progeny could be activated by chance.
owever, in agreement with the in vitro data, infusion
r implantation of allogeneic, MHC-mismatched
SCs into baboons has been well tolerated in most
nimals [88-90]. Unique immunologic properties of
SCs were also suggested by the fact that engraft-
ent of human MSCs occurred after intrauterine
ransplantation into sheep, even when the transplan-
ation was performed after the fetuses became immu-
ocompetent [91].
MSC neither fail to activate T cells nor are targets
or CD8 cytotoxic lymphocytes [92]. Phytohemag-
lutinin (PHA) blasts generated to react against a
peciﬁc donor will lyse chromium-labeled mononu-
lear cells from that individual, but not MSCs derived
rom the same donor. Furthermore, killer cell inhib-
tory receptor (KIR ligand)–mismatched natural killer
ells do not lyse MSCs [92]. Thus, MSCs, although
ncompatible at the MHC, escape the immune system.
hese in vitro data may suggest that allogeneic fetal or
dult MSCs can be transplanted without being re-
ected. However, although MSCs are transplantable
cross allogeneic barriers, a delayed type hypersensi-
ivity reaction leading to transplant rejection occurred
n a xenogenic model when human MSCs were re-
ected in immunocompetent rats [93]. In this study,
uman MSCs were identiﬁed in the heart muscle of
evere compromised immune deﬁciency rats, in con-
rast to that of immunocompetent rats. In the latter
roup, peripheral blood lymphocytes proliferated af-
er restimulation with human MSCs in vitro, thus
uggesting cellular immunization. Such a proliferative
esponse in vitro has not been detected in humans
reated with intravenous (IV) infusion of allogeneic
SCs (Le Blanc and Ringdén, unpublished data,004). s
24MMUNOMODULATION BY MSCS
The immunomodulatory effects of MSCs may
ake them useful for immunotherapy, although the
xact mechanism of action is unknown. As mentioned
reviously, MSCs are immunosuppressive and inhibit
-cell alloreactivity induced in mixed lymphocyte
ultures (MLCs) or by nonspeciﬁc mitogens [24-29,
7,94]. Whether they suppress lymphocyte responses
nduced by recall antigens is controversial [29,71,94].
SC-induced T-cell suppression seems to include
oth naive and memory T cells. It has no immuno-
ogic restriction; it is signiﬁcant whether the MSCs
re autologous with the stimulatory or the responder
ymphocytes or are derived from a third party [25-28].
his suggests that MSCs used in ASCT may not need
o be derived from the HSC donor. The degree of
SC suppression is dose dependent [26,29]. High
oses of MSC are inhibitory, whereas low doses en-
ance lymphocyte proliferation in MLCs. The T cells
o not become apoptotic or anergic, because they can
e restimulated if MSCs are removed [25,29].
MSCs decreased the expression of CD4 activa-
ion markers, CD25, CD38, and CD69 on PHA-
timulated lymphocytes [95]. Recent data suggest that
SCs increase the number of regulatory T cells [96].
ata from our own laboratory suggest that suppres-
ion may be mediated by different mechanisms, de-
ending on the T-cell stimulus [97]. For instance,
SCs increased the transcription and translation of
nterleukin (IL)–2 and soluble IL-2 receptors in
LCs, whereas the levels decreased if MSCs were
resent among the PHA-stimulated lymphocytes. T-
ell inhibition may occur before IL-2 is secreted.
SCs inhibit lymphocyte proliferation induced by
oncanavalin A. However, when IL-2 was added to
oncanavalin A–stimulated lymphocytes, the inhibi-
ion by MSCs was partly abrogated [25]. Furthermore,
oculture of MSCs with puriﬁed activated dendritic
ells led to decreased tumor necrosis factor  secretion
nd increased IL-10 secretion [96]. MSCs cocultured
ith effector T cells or puriﬁed natural killer cells led
o a decrease in IFN- secretion or an increase in IL-4
ecretion, respectively. Dependent on the kinetics,
SCs can enhance or depress IL-10 levels in MLCs
97]. These various effects may in part explain the
mmunosuppressive effects by MSCs in vitro.
The way in which MSCs suppress T-cell activa-
ion and modulate the immune response has not been
ompletely resolved. However, several mechanisms
ave been proposed, and MSCs have been shown to
ave various signiﬁcant effects. Suppression seems to
e mediated by a soluble factor or factors produced by
uman MSCs, because suppression still occurs if
SCs and lymphocytes are separated in a transwellystem [24,27,92]. It is unlikely that the factor(s) are
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Bonstitutively secreted by MSC, because cell-free
SC culture supernatants fail to suppress alloreactiv-
ty, whereas supernatants from MSC/lymphocyte co-
ultures are suppressive [29,95,98]. In contrast, in
ice, inhibition by MSCs was reported to require cell
ontact [28]. The soluble factors mediating the sup-
ressive effect were suggested to be composed of the
epatocyte growth factor and transforming growth
actor (TGF)– [24]. Experiments showed that the
ddition of anti–hepatocyte growth factor and anti–
GF- restored T-cell proliferation in the presence
f MSCs. However, we were unable to reproduce
hese experiments [95]. Aggarwal and Pittenger [96]
uggested that MSC-produced prostaglandin E2 ac-
ounted for reduced lymphocyte proliferation. An-
ther study suggests that indoleamine 2,3-dioxygen-
se–mediated tryptophan depletion by MSCs can act
s a T cell–inhibitory effector mechanism [99]. In-
oleamine 2,3-dioxygenase, which is induced by
FN-, catalyzes the conversion from tryptophan to
ynurenine and inhibits T-cell responses [100]. How-
ver, in the hands of Tse et al., neither MSC produc-
ion of IL-10, TGF-1, and prostaglandin E2 nor
ryptophan depletion in the culture medium was re-
ponsible for the immunosuppressive effect [27]. In
ddition, MSCs produce bone morphogenetic protein
, which may mediate immunosuppression via the
eneration of CD8 regulatory cells [98]. The con-
roversial data may be due to the use of MSCs gener-
ted by different techniques; the use of different stim-
li, culture conditions, doses, and kinetics; and
ifferent lymphocyte populations tested. Such differ-
nces may in turn affect cytokine and chemokine se-
able 1. Clinical Experience of Mesenchymal Stem Cells in Hematopoie
Disease
No.
Patients
Source of MSCs
Setting
ematologic malignancies 15 Autologous IV
infusion
reast cancer 28 Autologous in
autologous SC
nborn errors of metabolism 11 HLA-identical fr
SCT donor
steogenesis imperfecta 5 HLA-identical fr
SCT donor
cute myeloid leukemia 1 HLA-haploidenti
from SCT don
eukemia 31 HLA-identical fr
SCT donors
evere aplastic anemia 1 Allogeneic MSC
evere acute GVHD 1 Haploidentical M
unrelated don
SCTretion, with seemingly contradictory results. Fur- t
B & M Thermore, apparent species-speciﬁc differences,
articularly between murine and human MSCs, add to
he confusion [28]. A major problem is that MSCs
annot be identiﬁed by a speciﬁc marker or a combi-
ation of markers. One likely conclusion from the
vailable data is that several mechanisms are involved
n the MSC-mediated immunosuppressive effect.
First-trimester fetal liver–derived MSCs have dif-
erent immunomodulatory properties [85,86]. Fetal
SCs suppress mitogenic responses, but not alloreac-
ivity, in MLCs. However, when precultured with
FN- for full HLA class II expression, fetal MSCs
nhibit lymphocyte proliferation at a magnitude sim-
lar to that seen with adult MSCs. Thus, despite the
pregulation of class II alloantigens, other concurrent
vents induced by IFN- seem to enhance the anti-
roliferative effect that fetal MSCs exert on lympho-
yte proliferation.
LINICAL EXPERIENCE OF MSC INFUSION
There is an urgent need for better treatment and
revention of GVHD after ASCT. Therefore, the
linical experience with and safety of MSCs are of the
tmost interest. The published clinical experience of
SCs in the hematopoietic stem cell transplantation
etting is limited but is summarized in Table 1. A
hase I trial was performed to determine the feasibility
f collection, expansion, and IV infusion of human
SCs in the autologous setting [101]. Fifteen patients
articipated; 5 patients in each group received 1, 10,
nd 50  106 MSCs, respectively. No adverse reac-
Cell Transplantation
Outcome Study
No adverse events of 1, 10, and
50  106 cells
Lazarus et al. [101]
IV infusion was safe; autologous
SCT recovery was rapid
Koç et al. [102]
No immune response against
donor; improved nerve-
conduction velocity in
metachromatic leukodystrophy
Koç et al. [125]
Gene-marked MSCs engrafted;
new dense bone formation; few
fractures
Horwitz et al. [104]
SCT engraftment with no GVHD Lee et al. [133]
Rapid platelet engraftment; low
incidence of acute GVHD
Frassoni et al. [134]
Engraftment; improved stroma Fouillard et al. [139]
Clearance of grade IV acute
GVHD, twice
Le Blanc et al. [43]tic Stem
/SCT
T
om
om
cal
or
om
SC;
orions were observed.
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3After IV infusion, MSCs circulate in the human
ody for a short period. Koç et al. [102]. detected
irculating clonogenic MSCs in some, but not all,
atients within the ﬁrst hour of infusion, but not
hereafter. Human MSCs engraft in multiple tissues
nd demonstrate site-speciﬁc differentiation after in-
rauterine transplantation into sheep [91,103]. Poten-
ial in vivo engraftment in bone has also been shown
fter IV MSC infusion in children with osteogenesis
mperfecta (OI) [104] and in 1 patient with severe
plastic anemia [105]. However, in the vast majority of
eports, long-term engraftment of transplanted MSCs
as not been demonstrated.
SCS MAY ENHANCE ENGRAFTMENT
Because the bone marrow stromata that support
ematopoiesis may derive from MSCs, it is of interest
o study whether MSCs enhance hematopoiesis. After
SCT, the immune and hematopoietic systems are, in
ost cases, entirely donor in origin [106-108]. After
igh-dose chemoradiotherapy before autologous or
llogeneic stem cell transplantation, the marrow
troma is damaged and slow to reconstitute [56,109-
14]. Because damage to the stroma may affect hema-
opoietic engraftment after stem cell transplantation,
econstitution of stromal cells by infusion of MSCs
ay enhance hematopoiesis after transplantation. Be-
ause less than 1 in 10 000 cells in the bone marrow is
n MSC, a conventional bone marrow graft should
ontain at the most approximately 10 000 MSCs per
ilogram of recipient weight [10,47]. However, stro-
al progenitors are predominantly recipient in origin,
nd this suggests that MSCs have a limited capacity
or reconstituting the marrow microenvironment
57,115].
Nevertheless, both fetal and adult human MSCs
romote engraftment of unrelated and umbilical
ord–derived HSCs in nonobese-diabetic/severe
ompromised immune deﬁciency mice and fetal sheep
29,116-119]. Whether this is due to MSCs or to
peciﬁc cytokines needs to be determined. The en-
ancing effect is most prominent when the dose of
ematopoietic cells is limiting. In the study by Maitra
t al., 2 of 10 mice engrafted when transplanted with
low number of MSCs, whereas 8 of 10 mice cotrans-
lanted with umbilical cord blood cells and MSCs
howed persistent engraftment [29]. MSC support for
econstitution is not lineage restricted but involves
ells of myeloid, lymphoid, and megakaryocytic lin-
ages [118-120]. The mechanism of enhancement is
ot understood and may or may not require homing of
SCs to the marrow.
In an initial study to explore whether MSCs en-ance engraftment in autologous stem cell transplan- h
26ation in humans, MSCs were isolated and expanded
n breast cancer patients receiving peripheral blood
tem cell infusions [102]. Twenty-eight patients were
nfused IV with 1 to 2 106/kg MSCs. There were no
ases of toxicity. The median time to achieve an ab-
olute neutrophil count of 0.5  109/L was 8 days
range, 6-11 days). A platelet count of 20  109/L
as reached in a median of 9 days (range, 4-19 days).
he observed rapid hematopoietic recovery suggests
hat MSC infusion may have a positive effect on he-
atopoiesis in vivo. Controlled clinical trials are now
eeded to clarify whether MSCs have a role in accel-
rating hematopoietic engraftment after transplanta-
ion.
SCS FOR INBORN ERRORS OF METABOLISM
ASCT is indicated for several inborn errors of
etabolism [121-124]. MSCs express high levels of
rylsulfatase A and -l-iduronidase [57]. Arylsulfatase
deﬁciency is the cause of metachromatic leukodys-
rophy (MLD), and -l-iduronidase deﬁciency is the
ause of Hurler disease. To obtain further beneﬁcial
ffects by providing enzyme replacement to the tissue
hat MSCs distribute to, donor-derived MSCs were
xpanded and given IV to patients with MLD and
urler disease who had previously undergone ASCT.
leven patients were enrolled and infused with donor
SCs; they had no signiﬁcant toxicity within 15 to 31
onths of follow-up [125]. No immune response
gainst donor MSCs was detected with enzyme-linked
mmunospot assay using recipient lymphocyte and do-
or MSCs. Although there was no major improve-
ent in the overall health of the patients, in 4 of 5
atients with MLD, there was clear evidence of im-
rovement in nerve-conduction velocity.
STEOGENESIS IMPERFECTA
MSCs can differentiate into bone in vitro. There-
ore, MSCs may be useful in the treatment of bone
isorders. OI is caused by a mutation of 1 of the 2
enes that encode type I collagen. This genetic disor-
er leads to generalized osteopenia, bony deformities,
xcessive fragility with fracturing, and short stature.
here is no cure for OI, nor is there any effective
herapy [126].
In a mouse model of OI, MSCs expressing normal
ype 1 collagen were infused [127]. A small number of
onor MSCs and osteoblasts engrafted, and normal
ollagen was detected in the bone of the OI mice.
tudies in humans indicate a possible therapeutic ef-
ect of MSCs in OI [128]. In 5 children with OI,
epresentative specimens of trabecular bone showed
istologic changes indicative of new dense bone for-
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Mesenchymal Stem Cells Against GVHD
Bation after successful ASCT. All patients had an
ncrease in total body bone mineral content compared
ith predicted values for healthy children. These im-
rovements were associated with increased growth
elocity and fewer bone fractures. The data suggest
hat ASCT can lead to engraftment of functional
SCs, thus indicating the feasibility of this strategy in
he treatment of OI and maybe other MSC disorders.
urthermore, gene-marked MSCs were demonstrated
o engraft in children with OI [104]. These data en-
ouraged us to perform fetal MSC transplantation in
tero in a fetus with OI. A female fetus with bilateral
ntrauterine femur fractures, diagnosed with severe
I, underwent transplantation with HLA-mis-
atched male fetal MSCs in the 32nd week of gesta-
ion. At 9 months of age, a bone marrow biopsy
howed 7.4% Y-positive cells by ﬂuorescence in situ
ybridization (FISH). The bone was regularly ar-
anged, with conﬁgured bone trabeculae lined by a
olumnar layer of normal osteoblasts. During the ﬁrst
ear of life, this girl had only 2 suspected fractures: a
lavicular fracture at 6 weeks of age and a costal
racture at 9 months. The data showed that allogeneic
LA-mismatched fetal MSCs engraft and differenti-
te into bone in an immunocompetent fetus.
SCS IN ALLOGENEIC HSC TRANSPLANTATION
In ASCT, MSCs may be used to enhance engraft-
ent of white blood cells and platelets. Furthermore,
SCs may be used to modulate the immune system,
s prophylaxis to prevent GVHD, and as treatment for
stablished GVHD. Several studies have compared
one marrow and peripheral blood as a source of stem
ells in patients receiving allografts [129-131]. The
igher CD34 cell dose often obtained by using pe-
ipheral stem cell harvest is associated with faster
eutrophil and platelet engraftment. However, when
81 adult patients with acute myeloid leukemia in ﬁrst
omplete remission were retrospectively compared for
ransplant-related mortality, leukemia-free survival,
nd overall survival, the outcome was signiﬁcantly
etter for patients who received a high (2.7  108/
g) bone marrow dose than for high-dose peripheral
lood stem cell transplantation [132]. Because whole
one marrow contains many cell types, it is possible
hat accessory cells in the graft contribute to the im-
roved outcome when stem cell doses are similar.
hus, a graft engineered to include both a large stem
ell dose and an increased number of stromal precur-
or cells may further improve outcome in ASCT.
A 20-year-old woman with acute myeloid leuke-
ia received peripheral blood stem cells combined
ith MSCs from her HLA-haploidentical father133]. The patient engrafted rapidly, with no acute or M
B & M Thronic GVHD, and was doing well 31 months after
he ASCT. This is a most remarkable case. After
aploidentical transplantations with conventional im-
unosuppression, the risk of rejection or life-threat-
ning acute GVHD is substantial. This ﬁnding, of
ourse, needs to be conﬁrmed.
In a multicenter clinical trial, HSCs and MSCs
erived from HLA-identical sibling donors were in-
used to promote hematopoietic engraftment and
imit GVHD [134]. Thirty-one patients received my-
loablative conditioning and HLA-identical sibling
one marrow or peripheral blood stem cells. Escalat-
ng doses of MSC from 1 to 5  106/kg were given.
here were no incidences of MSC infusion–related
oxicity. The incidence of grade II to IV acute GVHD
as 15% in the cotransplanted group, compared with
0% in a matched control group (P  .01). The most
igniﬁcant difference was the higher platelet count on
ay 50 after transplantation in the cotransplanted
roup (P  .0001). Delayed platelet engraftment is a
nown risk factor for chronic GVHD [135]. In agree-
ent with an improved platelet reconstitution, the
ncidence of chronic GVHD was lower in the group
eceiving MSCs (12% versus 67% in the control
roup; P  .002). Survival at 6 months in the patients
eceiving MSCs was 88%, compared with 68% in the
ontrol group. This preliminary study suggests that
oinfusion of MSCs in ASCT may enhance engraft-
ent, decrease GVHD, and improve survival. These
ata have to be interpreted with caution, because the
tudy is not published in a refereed journal. Further-
ore, a new analysis has been performed with a
atched control group from the Centre of Interna-
ional Blood and Marrow Transplant Research. This
ew analysis has not yet been presented or published.
rospective dose-ﬁnding and randomized studies are
nder way in the United States and in Europe.
SCS FOR TREATMENT OF ACUTE GVHD
There is no successful therapy for steroid-refrac-
ory acute GVHD. The possible role of MSCs in this
ontext is therefore of potential interest. Recently, we
eported a case of grade IV acute GVHD of the gut
nd liver in a patient who had undergone ASCT with
ells from an unrelated female donor [43]. The male
atient was unresponsive to all types of immunosup-
ression, including prednisolone 2 mg/kg daily, re-
eated IV infusions of methylprednisolone, extracor-
oreal treatment with psoralen and UV-A light 1 to 4
imes per week for 6 weeks, inﬂiximab and daclizumab
or 4 weeks, mycophenolate mofetil, and methotrex-
te. He was treated for repeated bacterial, viral, and
nvasive fungal infections. After an infusion of 2 106SCs per kilogram from his HLA-haploidentical
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3other, his GVHD responded miraculously with a
ecline in bilirubin and normalization of stools. The
atient had high-risk acute lymphoblastic leukemia in
hird remission at the time of transplantation. After
he MSC infusion, DNA analysis of his bone marrow
howed the presence of minimal residual disease [136].
yclosporine treatment was discontinued to allow a
aximum graft-versus-leukemia effect. When immu-
osuppression was discontinued, the patient again de-
eloped severe acute GVHD, with diarrhea and an
ncrease in bilirubin to 360 mmol/L within a few
eeks.
Colonoscopy showed a normal colon with mild
VHD and 4% female epithelium detected by FISH.
e received a repeat infusion of MSCs from his
other (1  106/kg). After 1 week, his stools were
ormal, and he started to eat again. Bilirubin subse-
uently normalized. One year after transplantation, he
as home and well, with no minimal residual disease
n the blood or bone marrow. However, 1.5 years after
he transplantation, an attempt was made to discon-
inue immunosuppression, and the GVHD recurred.
mmunosuppression was again initiated. Unfortu-
ately, in the meantime, he developed repeated pneu-
onias requiring ventilation and died in his home
ospital 19 months after ASCT. Several lessons can be
earned from this case. In particular, MSCs exert ther-
peutic effects on severe GVHD, probably through
mmunosuppression and healing of the gut and liver.
lthough a profound immunomodulatory effect was
een, it is clear from this case that tolerance was not
nduced by MSCs. Immunosuppression with cyclo-
porine and steroids was needed because severe acute
VHD recurred after the withdrawal of cyclosporine.
owever, the same MSCs could be used again and had
he same dramatic effect on GVHD in the gut and
iver. In accordance with previous in vitro reports,
llogeneic HLA-incompatible MSCs did not induce
n immune response in vivo [24,26,27,84]. Further-
ore, a dose of 1  106 MSCs per kilogram seems
ufﬁcient for a prompt response. It could not be
roven that the female epithelial cells in the colon
etected by FISH were from the MSC donor, because
he HSC donor was also female. However, it is most
ikely that these cells were from the MSC donor,
ecause a study in baboons showed that MHC-mis-
atched MSCs became engrafted in gastrointestinal
issue after IV infusion [90,137].
Two additional patients with grade II to IV acute
VHD of the gut responded to MSC therapy from
heir respective HLA-identical ASCT donors at our
nit. Both patients were alive and well 32 and 6
onths after ASCT (Le Blanc and Ringdén, unpub-
ished data, 2005). A promising effect of MSCs on
cute GVHD has also been conﬁrmed in 1 patient
ho recovered from steroid-resistant acute GVHD e
28fter infusion of MSCs from an HLA-matched donor
y the team in Genua (Frassoni, personal communi-
ation, 2004). So far, our experience of using MSCs to
reat acute GVHD is limited to a few cases. Additional
ata from prospective controlled studies are needed,
nd such studies are under way.
UTURE PERSPECTIVES FOR MSCS IN ASCT
Many questions regarding MSCs cannot be an-
wered today. Most of what is known about MSCs is
erived from in vitro experiments. When adminis-
ered in vivo, MSCs have been difﬁcult or almost
mpossible to detect. There is very limited experience
ith MSCs administered to humans. For instance,
ene-marked MSCs were found to engraft in children
ith OI [104]. Using FISH, we were able to ﬁnd Y
hromosome–positive cells in a bone marrow biopsy
ample when male fetal MSCs were injected in utero
o a female recipient. In this patient, genomic HLA
yping by polymerase chain reaction (PCR) could not
etect any donor cells. Furthermore, we have not been
ble to identify donor HLA by PCR in any tissue after
V infusion of allogeneic MSCs. We can only specu-
ate about the difﬁculties in identifying MSCs in vivo.
any cells seem to lodge in the pulmonary vascular
ed, and in other tissues MSCs may appear with low
requency, if at all [138]. Clinical effects of MSCs have
learly been observed; however, it is possible that the
ffect of the MSCs has been due to local production of
rowth factors rather than to direct participation of
SCs in the healing process. After fulﬁlling this func-
ion, MSCs may have died. It cannot be excluded that
SCs may have been rejected in an allogeneic setting,
lthough an immune response in vitro, determined via
ymphocyte proliferation, has not been detected.
uch more work, especially in vivo, is required to
ncrease our knowledge of how MSCs act and their
ate. However, we need not wait for such additional
ata, because signiﬁcant effects, albeit anecdotal, have
lready been noted in the clinic.
One reason that it has been difﬁcult to detect
onor MSCs in bone marrow aspirates may be that
SCs are located in the endosteum [139]. In a 68-
ear-old woman with end-stage severe aplastic ane-
ia, MSCs from her son (107 MSCs per kilogram on
occasion and 6  106 MSCs per kilogram on an-
ther occasion) were injected. The bone marrow
howed donor chimerism by PCR that was not de-
ected in bone marrow aspirates. Such a discrepancy
etween bone marrow biopsies and aspirations has
lready been observed in baboons [88].
In HSC transplantation, MSCs may be important
or several indications. Overall, in ASCT, MSCs may
nhance engraftment of hematopoietic cells. This may
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Be particularly important in cord blood transplanta-
ion, in which the limited cell dose delays engraftment
f the absolute neutrophil count and platelets and in
hich there is an increased risk of graft failure
140,141]. Whether MSCs in this setting have immu-
omodulatory effects and prevent rejection remains to
e proven. Furthermore, with nonmyeloablative con-
itioning, the risk of graft failure is increased com-
ared with myeloablative conditioning [142].
hether MSCs enhance donor cell engraftment and
revent rejection may be worthwhile to explore. Be-
ause MSCs produce arylsulfatase A and -l-iduroni-
ase, cotransplantation with HSCs may also be im-
ortant in patients with various types of inborn errors
f metabolism [57]. The beneﬁcial role of MSCs in
his context may be more difﬁcult to assess, because
hese are rare disorders. MSCs may also be used as
VHD prophylaxis in ASCT, as indicated in the pilot
rial reported by Frassoni et al. [134].
Two prospective randomized studies are under
ay in Europe to address this issue. One is being
erformed in HLA-identical siblings by using MSCs
rom the HSC donor, and the other is being per-
ormed in recipients of unrelated ASCT, in which
SCs are expanded from the recipients’ haploidenti-
al sibling or parent. Because MSCs have immuno-
odulatory effects, it is also important to evaluate
heir effect on the graft-versus-leukemia effect. Acute
nd especially chronic GVHD decrease the risk of
eukemic relapse [143-145]. Assessment is therefore
eeded of whether cotransplantation with MSCs,
hile decreasing acute and chronic GVHD, can in-
rease the risk of leukemic relapse with an unchanged
eukemia-free survival.
Exogenously administered MSCs tend to survive
nd proliferate in the presence of malignant cells in
nimal models [146] .They seem to potentiate tumor
rowth in some solid tumors and exert an inhibitory
ffect in others [98,147]. Little is known about what
ffect MSCs have on leukemia. It is also important to
ssess whether MSCs depress immune responses
gainst infections caused by bacteria, fungi, and vi-
uses, which often compromise already-immunocom-
romised ASCT patients. Because of these concerns,
t is possible that MSCs may have their most impor-
ant application in the treatment of steroid-resistant
cute GVHD. Such patients have a high mortality
espite treatment with a wide range of new immuno-
uppressive drugs [30-42].
It has also been suggested that MSCs may be used
o treat rejections of organ allografts. Indeed, 1 rat
ardiac allograft study showed that MSCs home to the
ite of allograft rejection [148]. Furthermore, MSCs
ay have applications in autoimmune inﬂammatory
owel disease because of their immunomodulatory
B & M Tffect and their capacity for healing damaged gut ep-
thelium [43].
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